Kasper Bernd, Egerer Gerlinde, Gronkowski Martina, Haufe Sabine, Lehnert Thomas, Eisenhut Michael, Mechtersheimer Gunhild, Ho Anthony D, Haberkorn Uwe
Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Leuk Lymphoma. 2007 Apr;48(4):746-53. doi: 10.1080/10428190601113568.
Positron emission tomography (PET) using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) is used as a functional imaging technique for the staging and follow-up of lymphomas. However, additional information about the tumor proliferation rate using 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) may be useful for the assessment of prognosis. We enrolled 48 patients with Hodgkin's (n = 15) and non-Hodgkin's lymphoma (n = 33) with residual masses >2 cm examined by tracer studies with FDG and FLT. The results were related to median overall and progression-free survival. In 15 out of 48 patients analysed using FDG, positive results were found. Using FLT, 10 out of 48 patients were positive. 33 patients were FDG negative. Eight patients were positive both using FDG and FLT. Overall survival for patients with a negative PET scan was significantly higher than for patients with positive PET, irrespective of the tracer used. FLT alone was able to discriminate between patients with long or short overall survival. However, there was no statistical significance comparing FDG/FLT negative versus FDG negative alone. Although FDG detected more lesions than did FLT, the additional biological characterization of tumor tissue with respect to proliferation by FLT might be useful by providing complementary information for the identification of recurrence. However, the present data show no advantage of combined FDG/FLT studies over FDG alone with respect to the prediction of survival.
使用2-脱氧-2-[(18)F]氟-D-葡萄糖（FDG）的正电子发射断层扫描（PET）被用作淋巴瘤分期和随访的功能成像技术。然而，使用3'-脱氧-3'-[(18)F]氟胸苷（FLT）获得的关于肿瘤增殖率的额外信息可能有助于预后评估。我们纳入了48例霍奇金淋巴瘤（n = 15）和非霍奇金淋巴瘤（n = 33）患者，这些患者残留肿块>2 cm，通过FDG和FLT示踪研究进行检查。结果与中位总生存期和无进展生存期相关。在使用FDG分析的48例患者中，有15例结果为阳性。使用FLT时，48例患者中有10例为阳性。33例患者FDG为阴性。8例患者FDG和FLT均为阳性。PET扫描阴性患者的总生存期显著高于PET阳性患者，无论使用何种示踪剂。单独使用FLT能够区分总生存期长或短的患者。然而，比较FDG/FLT阴性与单独FDG阴性没有统计学意义。虽然FDG检测到的病变比FLT多，但FLT对肿瘤组织增殖的额外生物学特征描述可能通过提供补充信息来识别复发而有用。然而，目前的数据表明，在生存预测方面，联合FDG/FLT研究并不优于单独使用FDG。
